Core-g28v2 60mer mRNA Vaccine

Phase 1Vaccine

IInternational AIDS Vaccine Initiative

Core-g28v2 60mer mRNA Vaccine is one of 40 biologic programs targeting Immunogenicity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunogenicityActive, not recruiting

ImmunogenicityPhase 1

Active, not recruiting

Competition

Competitive Landscape

98 competitors in Immunogenicity

#DrugCompanyPhaseTrials

Perjeta

Roche

Phase 3

2 2

Rabies Vaccine

Novartis

Phase 3

12 3

Prolia

OOrganon and Co

Phase 3

2 4

Rsvpref

Pfizer

Phase 3

5 5

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

3 6

PCV21

Sanofi

Phase 3

2 7

Bexsero

GSK

Phase 3

8 8

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

2 9

Opfolda

Johnson & Johnson

Phase 3

1 10

Gardasil

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity1 trial

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Active, not recruiting·IInternational AIDS Vaccine Initiative·Phase 1·NCT05001373·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Core-g28v2 60mer mRNA Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Core-g28v2 60mer mRNA Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Core-g28v2 60mer mRNA Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — International AIDS Vaccine Initiative company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: IInternational AIDS Vaccine Initiative

Core-g28v2 60mer mRNA Vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News